Introduction: Induction therapy has been recently adopted for intestinal transplant. Patients and methods: We compared during first 30 days post-transplantation 29 recipients, allocated in two groups, treated with Daclizumab (Zenapax®) or Alemtuzumab (Campath-1H®). Results: During first month, 45% of Daclizumab recipients experienced six acute cellular rejections (ACRs) of mild degree, while 63% of them developed an infection requiring treatment. We found three acute cellular rejections in 17.6% of Alemtuzumab recipients, two with moderate degree; 64.7% of them required treatment for infection. Discussion and conclusions: Graft and patient 3-years cumulative survival rate were not significantly different between groups. Alemtuzumab seems to offer a better immunosuppression during first month. © 2006 Editrice Gastroenterologica Italiana S.r.l.
Daclizumab and Alemtuzumab as induction agents in adult intestinal and multivisceral transplantation: A comparison of two different regimens on 29 recipients during the early post-operative period / Lauro A.; Amaduzzi A.; DAZZI, ALESSANDRO; ERCOLANI, GIORGIO; Zanfi C.; GOLFIERI, LUCIA; GRAZI, GIAN LUCA; VIVARELLI, MARCO; CESCON, MATTEO; VAROTTI, GIOVANNI; DEL GAUDIO, MASSIMO; Ravaioli M.; SINISCALCHI, ANTONIO; FAENZA, STEFANO; D'ERRICO, ANTONIETTA; DI SIMONE, MASSIMO PIERLUIGI; PIRONI, LORIS; PINNA, ANTONIO DANIELE. - In: DIGESTIVE AND LIVER DISEASE. - ISSN 1590-8658. - STAMPA. - 39:(2007), pp. 253-256. [10.1016/j.dld.2006.11.012]
Daclizumab and Alemtuzumab as induction agents in adult intestinal and multivisceral transplantation: A comparison of two different regimens on 29 recipients during the early post-operative period
GRAZI, GIAN LUCA;
2007
Abstract
Introduction: Induction therapy has been recently adopted for intestinal transplant. Patients and methods: We compared during first 30 days post-transplantation 29 recipients, allocated in two groups, treated with Daclizumab (Zenapax®) or Alemtuzumab (Campath-1H®). Results: During first month, 45% of Daclizumab recipients experienced six acute cellular rejections (ACRs) of mild degree, while 63% of them developed an infection requiring treatment. We found three acute cellular rejections in 17.6% of Alemtuzumab recipients, two with moderate degree; 64.7% of them required treatment for infection. Discussion and conclusions: Graft and patient 3-years cumulative survival rate were not significantly different between groups. Alemtuzumab seems to offer a better immunosuppression during first month. © 2006 Editrice Gastroenterologica Italiana S.r.l.File | Dimensione | Formato | |
---|---|---|---|
1-s2.0-S1590865806006050-main.pdf
Accesso chiuso
Dimensione
212.08 kB
Formato
Adobe PDF
|
212.08 kB | Adobe PDF | Richiedi una copia |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.